

GlaxoSmithKline Pharma

BSE SENSEX 77,210 S&P CNX 23,501



Stock Info

Bloomberg	GLXO IN
Equity Shares (m)	169
M.Cap.(INRb)/(USDb)	429.9 / 5.1
52-Week Range (INR)	2760 / 1377
1, 6, 12 Rel. Per (%)	4/36/52
12M Avg Val (INR M)	346
Free float (%)	25.0

Financials Snapshot (INR b)

Y/E MARCH	FY24	FY25E	FY26E
Sales	34.5	37.3	40.7
EBITDA	9.1	9.9	11.1
Adj. PAT	7.3	7.8	8.6
EBIT Margin (%)	24.3	24.7	25.4
Cons. Adj. EPS (INR)	43.3	45.8	50.8
EPS Gr. (%)	20.5	5.7	10.9
BV/Sh. (INR)	104.9	123.1	146.3

Ratios

Net D:E	-0.6	-0.5	-0.6
RoE (%)	41.3	37.2	34.7
RoCE (%)	40.4	40.2	37.7
Payout (%)	61.1	63.1	56.9

Valuations


P/E (x)	58.6	55.4	50.0
EV/EBITDA (x)	36.8	33.8	29.9
Div. Yield (%)	0.9	0.9	0.9
FCF Yield (%)	2.9	1.2	2.6
EV/Sales (x)	9.7	9.0	8.1

Shareholding pattern (%)

As On	Mar-24	Dec-23	Mar-23
Promoter	75.0	75.0	75.0
DII	7.9	8.7	10.3
FII	3.5	2.9	2.3
Others	13.6	13.4	12.4

FII Includes depository receipts

Stock performance (one-year)



CMP: INR2,538 **TP: INR2,380 (-6%)** **Neutral**

Business in recovery mode!

Valuation adequately factors in the earnings upside

- GlaxoSmithKline Pharma (GLXO), a domestic-focused player, reported a moderate revenue/EBITDA/PAT growth of 3%/10%/14% over FY18-23.
- In FY24, GLXO exhibited a healthy pick-up with 6.2%/13.0%/20.5% YoY growth in revenue/EBITDA/PAT, fueled by increased NLEM-based product volumes, takeoff of its vaccines business (from 3QFY24), and traction in new launches.
- Considering an 8% earnings CAGR and a stabilizing return ratio of ~35% over FY24-26E, we value GLXO at 45x 12M forward earnings to arrive at our TP of INR2,380. We believe the current valuation as well as ~84% stock appreciation over the past one year adequately factors in the upside in earnings. Hence, we reiterate our Neutral rating on the stock.

Enhanced effort in Rx drives FY24 sales growth despite the NLEM impact

- In FY24, GLXO's ex-vaccines business posted high-single-digit growth despite the addition of key brands, such as Ceftum and T-Bact in NLEM. The growth was propelled by a surge in volumes of Ceftum/T-Bact (+56% / +10%).
- GLXO has consistently underperformed IPM over FY18-23, due to a higher share of revenue from acute therapies, 40% of its generic medicine portfolio being under NLEM, and a slower takeoff of key therapies such as vaccines.
- GLXO has the highest share from acute therapies (94% of total FY24 sales), which has underperformed IPM by 410bp over MAT Apr'20-24.
- Further, the company's key therapies, such as Derma, Anti-infective, Pain, and Hormones have all underperformed IPM.
- Over the last two years, however, Trelegy Ellipta has witnessed decent growth in the specialty portfolio.
- GLXO's ex-vaccines business is likely to drive growth, led by increased awareness of its brands through campaigns & advertisements, a focus on growing newly launched brands, and niche launches in its specialty portfolio.

Efforts underway to scale-up the vaccines business

- Over FY22-24, GLXO's vaccines business declined due to a slower takeoff of its vaccines during the pandemic and an increase in offerings in the National Immunization Program (NIP).
- However, the vaccines business has stabilized now and delivered growth in 3Q/ 4QFY24, led by the traction in pediatric vaccines, adult vaccines, and growth in products included in NIP.
- GLXO is implementing efforts to improve the growth prospects of its vaccines business by increasing awareness of both pediatric and adult vaccines, relaunching older brands (like Viralix), and launching new brands.

Valuation and view

- We expect GLXO to deliver a revenue/EBITDA/PAT CAGR of 9%/10%/8% over FY24-26, aided by: a) an increase in brand awareness, b) new launches in vaccines and specialty segment, c) volume takeoff in NLEM portfolio, and d) traction in new launches such as Trelegy Ellipta/Shingrix.
- We await clarity on any further launches from the parent portfolio.
- **We value GLXO at 45x 12M forward earnings to arrive at our TP of INR2,380.** Considering an 8% earnings CAGR and a stabilizing return ratio of ~35% over FY24-26E, we believe the current valuation adequately factors in the earnings upside. **Reiterate Neutral.**


Exhibit 1: Valuation snapshot

Company	Reco	MCap (USD b)	DF Sales		EPS (INR)			EPS Gr. YoY (%)		PE (x)		EV/EBITDA (x)		ROE (%)		
			FY24 (INR b)	FY24	FY24	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E	FY24	FY25E	FY26E
MNC Pharma																
Abbott India*	Not Rated	6.8	58	565	718	922	27.0	28.4	42.7	37.5	33.3	29.4	34.9	32.8	46.2	
GSK Pharma	Neutral	5.2	35	43	46	51	5.7	10.9	55.4	50.0	33.8	29.9	41.3	37.2	34.7	
Sanofi*	Not Rated	1.9	21	262	316	336	20.5	6.4	25.5	22.5	19.3	16.1	52.7	36.2	47.8	
Pfizer*	Not Rated	2.7	22	122	131	157	7.4	19.8	37.0	30.8	28.5	24.5	16.2	15.8	17.1	
Large-Cap Indian Pharma																
Alkem	Neutral	7.3	84	159.7	173.1	192.2	8.4	11.0	29.4	26.5	23.6	20.6	19.7	18.6	17.9	
Cipla	Buy	7.4	84	159.7	173.1	192.2	8.4	11.0	30.0	27.0	24.1	21.0	19.7	18.6	17.9	
Dr Reddy's Labs	Neutral	15	109	52.5	58.9	65.8	12.3	11.7	26.5	23.7	17.2	15.1	15.9	15.4	14.9	
Lupin	Neutral	11.9	46	317.1	323.9	339.1	2.1	4.7	18.4	17.6	10.4	9.4	20.7	17.7	15.9	
Sun Pharma	Buy	8.6	67	41.5	50.2	58.7	20.9	16.9	31.3	26.8	16.8	14.4	14.1	14.9	15.1	
Torrent Pharma	Neutral	43.3	149	41.4	47.0	57.6	13.5	22.4	32.0	26.1	24.7	20.2	16.7	16.5	17.4	
Zydus Life Science	Neutral	11.7	50	47.1	64.7	80.4	37.4	24.3	44.4	35.7	24.6	21.1	24.4	29.0	32.9	
Mankind Pharma	BUY	12.9	54	37.6	41.3	42.8	9.7	3.6	26.0	25.1	17.3	16.3	20.3	18.5	16.1	
Mid-Cap Indian Pharma																
Ajanta Pharma	Buy	3.6	12	62.3	74.4	85.4	19.4	14.9	32.3	28.1	21.7	18.7	22.7	24.0	23.1	
Alembic Pharma	Neutral	2	22	31.5	35.7	40.2	13.7	12.6	24.1	21.4	16.8	14.7	13.5	13.6	13.6	
Eris Lifescience	Neutral	1.7	20	29.2	33.1	44.4	13.1	34.1	31.4	23.4	17.8	15.2	16.8	16.4	18.9	
Glenmark Pharma	Neutral	4.1	34	2.5	44.1	50.4	NA	14.4	28.1	24.6	14.6	12.9	0.8	14.8	14.7	
IPCA Labs	Neutral	3.6	31	20.8	31.3	40.2	50.4	28.7	36.3	28.2	18.3	15.5	8.7	11.9	13.7	
JB Chemical*	Not Rated	3.3	19	35.7	54.3	64.4	52.4	18.5	39.9	33.1	25.8	22.2	20.5	22.5	21.3	

Source: MOFSL, Company


About 40% of GLXO's general medicine portfolio under NLEM

■ NLEM Portfolio
■ Non NLEM portfolio



GLXO generates 18% revenue from the vaccines business in FY24

■ Vaccine Business
■ Ex Vaccine Business




Improved Rx performance despite the NLEM impact; the vaccines business also in scale-up mode

- GLXO clocked a 3% CAGR over FY18-24, underperforming the IPM due to muted growth in its key therapies such as Respiratory, Vaccines, Hormones, and Pain segments.
- However, it delivered a high-single-digit YoY growth in revenue (ex-vaccines) in FY24, despite the addition of products under NLEM, with their share in overall revenue rising to 42% at the end of FY23 from 33% in CY22.
- During FY22-24, GLXO's vaccines business declined. However, it has stabilized now and is witnessing growth fueled by increasing awareness of new launches/base portfolio, relaunch of brands like Viralix, and new launches.
- GLXO remains committed to building a strong brand franchise, improving volumes, and launching new products under its specialty portfolio business. Further, the company is expected to raise awareness of its brands through campaigns & advertisements, and focus on growing its newly launched brands – Shingrix and Trelegy Ellipta.
- We expect 9% sales CAGR during FY24-26.

Ex-vaccines, GLXO recovers in the DF business in FY24

- GLXO (ex-vaccines) clocked a CAGR of 3% over FY18-24 and underperformed IPM by ~700bp over the same period. GLXO underperformed IPM in Respiratory/Hormones/Pain by 7.4%/7.0%/2.1%.
- In FY18, the revenue was flat YoY due to divestment and discontinuations of the brands coupled with the impact of GST implementation. However, the company reported 6.4% YoY growth in FY19, fueled by a change in the new marketing model, and the launch of key brands, including Nucala.
- In FY20, GLXO registered a modest revenue decline of 0.9% YoY due to the global recall of ranitidine, including Zinetac in India.

Exhibit 2: GLXO clocked 9% YoY growth in the ex-vaccines business in FY24




Source: MOFSL, Company, IQVIA

- In FY21, GLXO posted a decline of 15% YoY due to the Covid-19 impact and the sale of key brands such as Iodex and Ostocalcium.
- In FY22, GLXO experienced a spike of 12% YoY due to the low base in FY21 and market share gains in other key brands and therapies. Further, the growth was driven by general medicines such as Calpol and Augmentin due to the onset of the pandemic.
- In FY23, the ex-vaccines business growth moderated to 1.7% YoY owing to the inclusion of key brands in NLEM in 4QFY23. This was, however, offset by higher volumes and growth momentum in specialty brands (Nucala/Trelegy Ellipta).
- During FY24, GLXO grew 6.2% YoY driven by volume growth in NLEM brands like Ceftum/T-Bact (+56%/+10%) and market share gains in the specialty portfolio.

Gradual recovery in the vaccines business from 3QFY24

- The vaccines business clocked a 4.5% CAGR over FY18-24, 150bp higher than the ex-vaccine business.
- Especially, over FY19-21, the vaccines business recorded a double-digit growth led by new launches and market share gains. During the same period, GLXO launched Infanrix Hexa/Menveo/Fluarix Tetra, which garnered a strong volume share.

Exhibit 3: Vaccines business declined for three consecutive years




- GLXO's vaccines business declined for three consecutive years (FY22-24) due to the slower takeoff of vaccines during the pandemic and the increase in offerings in NIP. This was offset by a ramp up in the base business and the launch of the Shingrix vaccine (in Apr'23) in 3QFY24/4QFY24.
- GLXO is witnessing strong growth in pediatric vaccines after two years of stabilization. It is implementing efforts to improve the growth prospects of its pediatric vaccines segment, led by increasing awareness among parents and setting up plans with the pediatric association to drive growth.
- Additionally, with the launch of Shringrix, the company has entered into the adult vaccination business. GLXO is implementing efforts to create awareness among patients through advertisements. Further, it has started the supplies of Viralix again, which would drive growth.

Subdued performance in acute/chronic segments as per IQVIA over the past three years


- GLXO's acute therapies (94% of DF sales in MAT Apr'24) underperformed IPM (62% of DF sales) by 410bp over MAT Apr'20-24 .
- GLXO's chronic therapies (6% of DF sales in MAT Apr'24) underperformed IPM (38% of DF sales) by 780bp over MAT Apr'20-24.

Exhibit 4: GLXO's acute and...



Source: MOFSL, IQVIA


Exhibit 5: ...chronic therapies mostly underperformed IPM



Source: MOFSL, IQVIA


- During FY20-23, the overall growth was led by price hikes. In FY24, the price growth moderated abruptly to 0.2%.

Exhibit 6: Volume growth on a downtrend post-FY22




Note: GLXO's data excludes vaccine business Source: MOFSL, IQVIA

Exhibit 7: No price hikes in FY24




Note: GLXO's data excludes vaccine business Source: MOFSL, IQVIA

Derma is GLXO's biggest therapy, contributing 29% to its sales



- During FY20-24, the volume growth performance was a mixed bag; GLXO did not benefit from new launches over this period.

Exhibit 8: New launches did not benefit the company



Note: GLXO's data excludes vaccine business Source: MOFSL, IQVIA

Weak seasonality and inclusion of products in NLEM drag overall performance of key therapies

- In MAT Apr'24, GLXO's derma portfolio underperformed IPM by 360bp due to weaker seasonality as it is more acute-focused. However, over MAT Apr'21-23, the derma segment of GLXO (29% of total sales) outperformed IPM growth. GLXO's growth was in line with IPM-derma in MAT Apr'22 due to Covid-related restrictions.
- GLXO's anti-infective therapy (24% of total sales) underperformed IPM in MAT Apr'24 due to weak seasonality. While GLXO posted double-digit growth in MAT Apr'22 fueled by Covid-tailwinds, it underperformed IPM by 500bp. In MAT Apr'23, however, GLXO significantly outperformed IPM driven by the new SKU launches like Calpol 650+/Augmentin ES, which supported volume growth in the base business.

Exhibit 9: Barring FY24, derma has mostly outperformed IPM





Exhibit 10: Anti-infective broadly underperformed IPM



- GLXO's pain segment (12% of total sales) underperformed IPM during MAT Apr'23/24 due to inclusion of its key brand Calpol under the NLEM.

Exhibit 11: Hormones mostly underperformed IPM over MAT Apr'20-24





Exhibit 12: Pain mostly underperformed IPM over MAT Apr'23-24



- Hormones (8% of total sales) mostly underperformed IPM over MAT Apr'21-24. However, GLXO outperformed IPM in MAT Apr'23 led by strong growth in its key brand Eltoxin.

Top nine brands growing faster than IPM

- Augmentin, an anti-biotic with a market share of 48%, demonstrated a decent growth of 12% during MAT Apr'20-24. It outperformed therapy by 430bp over MAT Apr'20-24.
- T-Bact is used in the treatment of skin infections, such as impetigo (red sores), recurring boils, and others. It is growing faster than the IPM at 16.5% during MAT Apr'20-24. In MAT Apr'23, GLXO reported a 34% YoY growth due to strong execution. However, in MAT Apr'24, the growth declined due to inclusion of the brand under NLEM in late 2022 and seasonality, offset by increased volumes.
- Infanrix Hexa, used for the treatment of six diseases, viz, diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis (polio), and Haemophilus influenzae type b (Hib), clocked a 12.2% CAGR over MAT Apr'20-24. It significantly outperformed therapy growth by 13.7%.

Exhibit 13: Almost all the top brands driving growth

Drug	Molecule	Therapy	MAT Apr'24 Sales (INRm)	YoY Growth %	Brand 4 CAGR %	Therapy 4 CAGR %	Molecule 4 CAGR %
Augmentin	Amoxy. & clav.	Anti-infective	8102	0.7	12.3	8	12.3
Betnovate	Betameth.+comb.	Derma	6025	2.9	6	9.4	6
Calpol	Paracetamol + comb.	Pain	4937	-5.4	11.8	8.7	10.4
T-Bact	Mupirocin	Derma	3650	-3.1	16.5	9.4	16.5
Eltroxin	Levothyroxine	Hormones	2580	1.0	6.1	5.1	6.1
Ceftum	Cefuroxime	Anti-infective	2279	-28.7	0.9	8	0.9
Neosporin	Antibio. Comb.	Derma	2127	20	18.8	9.4	18.8
Infanrix hexa	Dpt+hib+polio+hep b	Vaccine	2012	17.2	12.2	-1.5	12.2
Betnesol	Betamethasone	Hormones	1638	-1.5	6	5.1	5.9
Ccm	Calcium	VMN	1463	10	16.2	10.3	17.3
Otrivin	Oxymetazoline	Respiratory	1317	-3.2	18.3	2.3	11.3

Source: MOFSL, IQVIA

- However, GLXO's key brand, Ceftum, underperformed IPM due to its inclusion in NLEM pricing. The decline was 29% YoY in MAT Apr'24 due to weak seasonality.

New launches exhibiting strong traction to aid growth over medium term

- With the launch of Shringrix (in Apr'23), the company has entered into the adult vaccination business. Shringrix is used to prevent herpes zoster in adults with age of 50 years and above. It has 100% market share in this category. Since the launch, GLXO has administered 55,000 dosages and garnered sales of INR167m in MAT Apr'24. It plans to administer 0.3-0.5m dosage over the next five years.
- Since the launch in Apr'22, Trelegy Ellipta has garnered revenue of INR85m (+155% YoY in MAT Apr'24). Trelegy Ellipta is used for the treatment of COPD, including chronic bronchitis, emphysema, or both, and to treat asthma in adults.

Exhibit 14: Pick-up witnessed in new launches


Drug	Molecule	Therapy	MAT Apr'24 Sales (INRm)	Date of Launch
Shingrix	Herpes Zoster / Shingles	Vaccines	167	Apr'23
Trelegy Ellipta	OTHER COMB. BRONCHO.INH	Respiratory	85	Apr'22
Centrum	FOOD SUPPLEMENTS+ CALCIUM + COLECALCI.	VMN	54	Sep'22

Source: MOFSL, IQVIA

- Centrum, launched in Sep'22, is used to improve bone health/skin/nails. Since its launch, the takeoff was slow; however, in MAT Apr'24, GLXO posted a strong growth in this brand with sales of INR54m. Centrum has three sub-brands, viz., Centrum Women, Centrum Men, and Centrum Osto.

Expect 9% CAGR over FY24-26 on overall basis

- We expect the growth momentum to strengthen over the next 2-3 years, aided by: 1) a scale-up in the vaccines business, b) price optimization in the overall portfolio, c) improved omni-channel experience for healthcare professionals despite reduction in field force, and d) cost efficiencies.

Exhibit 15: DF business to register a CAGR of 9% over FY24-26E

Source: MOFSL, Company

- Management expects a strong double-digit growth going forward backed by increased patient coverage, increasing awareness, approval for phase 4 study of Zejula/Jamperli, volume growth in generics, and new launches.
- Further, it has two assets under oncology, which are approved and ready to market. Post-launch, these would boost the specialty portfolio. Besides, GLXO expects that its recent launch, Shingrix, would drive growth in adult vaccination.
- Accordingly, we expect a sales CAGR of 9% over FY24-26 to INR40.7b.

Story in charts

Exhibit 16: Revenue CAGR of 9% over FY24-26E




Exhibit 17: Margin to improve over FY24-26E




Exhibit 18: Earnings CAGR of ~8% over FY24-26E




Exhibit 19: Cash likely to be distributed to stakeholders




Exhibit 20: P/E chart





Exhibit 21: EV/EBITDA chart



Financials and valuations

Income Statement								(INR m)
Y/E December	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E
Net Sales	31,281	32,244	29,256	32,780	32,517	34,537	37,331	40,691
Change (%)	8.0	3.1	-9.3	12.0	-0.8	6.2	8.1	9.0
EBITDA	6,008	6,573	5,981	7,639	8,043	9,087	9,932	11,053
Change (%)	18.8	9.4	-9.0	27.7	5.3	13.0	9.3	11.3
Margin (%)	19.2	20.4	20.4	23.3	24.7	26.3	26.6	27.2
Depreciation	486	827	786	682	658	697	712	737
EBIT	5,522	5,746	5,195	6,957	7,385	8,390	9,220	10,316
Int. and Fin. Charges	6	63	35	20	18	18	12	12
Other Income - Rec.	1,023	790	1,106	758	1,007	1,226	1,300	1,350
PBT	6,540	6,472	6,266	7,695	8,374	9,598	10,508	11,654
Tax	2,373	1,698	1,667	1,953	2,288	2,262	2,753	3,053
Tax Rate (%)	36.3	26.2	26.6	25.4	27.3	23.6	26.2	26.2
Adj PAT	4,167	4,775	4,596	5,739	6,086	7,336	7,755	8,600
Change (%)	25.2	14.6	-3.8	24.9	6.0	20.5	5.7	10.9
One-off income (net of tax)	-21	-3,843	-1,726	116	10	-1,436	0	0
Reported PAT Before Disc. Operations	4,454	932	2,873	5,858	6,096	5,900	7,755	8,600

Balance Sheet								(INR m)
Y/E December	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E
Equity Share Capital	1,694	1,694	1,694	1,694	1,694	1,694	1,694	1,694
Reserves	19,687	16,495	13,280	24,919	16,923	16,065	19,144	23,069
Capital Reserve	17	17	17	17	17	17	17	17
Net Worth	21,398	18,206	14,991	26,630	18,634	17,776	20,855	24,780
Loans	2	0	0	0	0	0	0	0
Capital Employed	21,400	18,206	14,991	26,630	18,634	17,777	20,856	24,781
Gross Block	5,590	10,190	6,740	7,740	8,740	8,131	8,631	9,131
Less: Accum. Deprn.	1,278	2,105	2,891	3,573	4,230	4,927	5,639	6,376
Net Fixed Assets	4,300	7,566	3,843	3,294	4,510	3,204	2,991	2,754
Capital WIP	10,026	1,201	132	305	203	139	139	139
Investments	17	15	14	3,668	5,194	8,141	8,141	8,141
Curr. Assets	24,148	21,469	26,114	37,934	23,245	22,619	24,802	30,465
Inventory	4,865	4,830	5,467	5,347	4,600	5,251	5,488	5,982
Account Receivables	1,205	998	2,156	2,052	1,924	2,221	2,053	2,238
Cash & Bank Balance	11,714	10,832	11,580	24,845	11,559	10,632	10,168	14,514
Others	6,364	4,808	6,911	5,689	5,162	4,516	7,093	7,731
Curr. Liability & Prov.	17,713	13,149	16,143	19,703	15,853	17,789	16,681	18,182
Account Payables	13,642	7,763	11,006	13,801	9,127	11,379	8,959	9,766
Provisions	4,071	5,386	5,137	5,902	6,726	6,410	7,722	8,417
Net Current Assets	6,435	8,319	9,971	18,231	7,392	4,830	8,121	12,283
Deferred Tax Assets	622	1105	1031	1132	1336	1462	1463	1463
Appl. of Funds	21,400	18,206	14,991	26,630	18,634	17,776	20,856	24,781

E: MOFSL Estimates

Financials and valuations

Ratios

Y/E December	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E
EPS	24.6	28.2	27.1	33.9	35.9	43.3	45.8	50.8
Cash EPS	27.5	33.1	31.8	37.9	39.8	47.4	50.0	55.1
BV/Share	126.3	107.5	88.5	157.2	110.0	104.9	123.1	146.3
DPS	20.0	20.0	30.0	30.0	20.0	22.0	24.0	24.0
Payout (%)	97.9	85.4	133.1	106.6	67.0	61.1	63.1	56.9
Valuation								
P/E	103.1	90.0	93.5	74.9	70.6	58.6	55.4	50.0
Cash P/E	92.4	76.7	79.9	66.9	63.7	53.5	50.8	46.0
P/BV	20.1	23.6	28.7	16.1	23.1	24.2	20.6	17.3
EV/Sales	10.9	10.6	11.7	9.9	10.4	9.7	9.0	8.1
EV/EBITDA	56.9	52.1	57.2	42.6	41.9	36.8	33.8	29.9
Dividend Yield (%)	0.8	0.8	1.2	1.2	0.8	0.9	0.9	0.9
Return Ratios (%)								
RoE	19.5	26.2	30.7	21.6	32.7	41.3	37.2	34.7
RoCE	19.9	24.3	27.9	27.7	26.9	40.4	40.2	37.7
Working Capital Ratios								
Fixed Asset Turnover (x)	8.3	5.4	5.1	9.2	8.3	9.0	12.1	14.2
Debtor (Days)	14	11	27	23	22	23	20	20
Inventory (Days)	57	55	68	60	52	55	54	54
Creditor days	159	88	137	154	102	120	88	88
Leverage Ratio								
Debt/Equity	-0.5	-0.6	-0.8	-0.9	-0.6	-0.6	-0.5	-0.6

Cash Flow Statement

(INR m)

Y/E December	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E
Oper. Profit/(Loss) bef. Tax	5,987	2,730	4,255	7,755	8,053	9,087	9,932	11,053
Interest/Div. Recd.	1,023	790	1,106	758	1,007	1,226	1,300	1,350
Direct Taxes Paid	-1,958	-2,180	-1,594	-2,053	-2,491	-2,389	-2,754	-3,053
(Inc)/Dec in WC	-619	-2,766	-904	5,006	-2,447	1,635	-3,755	184
CF from Operations	4,434	-1,427	2,864	11,465	4,121	9,559	4,723	9,534
EO expense	-21	-3,843	-1,726	116	10	0	0	0
CF from Op. incl. EO exp.	4,095	4,905	5,384	12,143	4,111	9,559	4,723	9,534
(inc)/dec in FA	-2,367	4,225	4,519	-1,173	-898	673	-500	-500
Free Cash Flow	1,707	5,287	8,177	11,086	3,223	10,232	4,223	9,034
(Pur)/Sale of Investments	1	2	1	-3,655	-1,526	173	0	0
CF from investments	-1,535	-568	4,180	-4,055	-2,424	846	-500	-500
Change in Equity capital	847	-	0	0	0	0	0	0
Inc/(Dec) in Debt	-4	-2	0	0	0	0	0	0
Interest Paid	-6	-63	-35	-20	-18	-18	-12	-12
Dividend Paid	-4,080	-4,078	-6,117	-6,117	-4,078	-4,486	-4,894	-4,894
CF from Fin. Activity	-3,583	-4,276	-6,560	-9,278	-14,975	-6,774	-4,690	-4,690
Inc/Dec of Cash	-1,023	60	3,004	-1,190	-13,287	3,631	-466	4,344
Add: Beginning Balance	2,011	988	1,048	4,052	2,862	-10,425	-6,794	-7,261
Closing Balance	988	1,048	4,052	2,862	-10,425	-6,794	-7,261	-2,916
Bank balances other than cash	10,725	9,784	7,528	21,983	21,983	21,983	21,983	21,983
Closing Balance	11,714	10,832	11,580	24,845	11,559	10,632	10,168	14,514

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal Capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal Capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.
- The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
- Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no warranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alterations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022-71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/NCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.